 ARCA biopharma, Inc. ABIO a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in a registered direct offering, 348,000 shares of ARCAs common stock, at a purchase price of 9.00 per share, and pre-funded warrants to purchase 694,222 shares of common stock at a purchase price of 8.999 per warrant. The gross proceeds to ARCA, before deducting placement agent fees and other offering expenses, are expected to be approximately 9.4 million. JonesTrading Institutional Services LLC is acting as the exclusive placement agent for the offering. 